Allergy expert Dr Hugh Sampson joing DBV Technologies
pharmafile | July 9, 2015 | Appointment | Research and Development | DBV Technologies, Viaskin
DBV Technologies has appointed Dr Hugh Sampson as its chief scientific officer.
The French biotech company is developing the Viaskin peanut allergy treatment patch.
Dr Sampson is a professor of paediatrics at the Icahn School of Medicine at the Mount Sinai School in New York. He is also the director of the Jaffe Food Allergy Institute and the dean of translational biomedical science at The Mount Sinai Medical Center.
He will join on November 1, and will also remain an advisor to the company and he will continue on as the director of the research center at the Jaffe Food Allergy Institute in New York.
Dr Pierre-Henri Benhamou, chairman and chief executive of DBV Technologies, says: “Today marks a very important day for us. One of the world leaders in medical research in food allergy and immunology is joining our leadership team, and we are honored to welcome him to DBV.
“We believe that Hugh’s vision and unique experience will bring a lot of value as we seek to expand our platform in the coming years. By joining forces, we hope to make great strides both in research and clinical development. We share the same commitment to innovation and the same ambition to change the lives of millions of food allergic patients.”
And Dr Sampson says: “I am very excited to join the DBV team and look forward to exploring the potential of this innovative platform. In my short tenure as a member of the DBV Scientific Advisory Board, I have been very impressed with the dedication and energy of everyone at DBV and their desire to understand the basic science underlying this immunotherapeutic approach, which has the potential to benefit millions of food allergic patients.”
